Literature DB >> 29758838

Tissue microarrays: leaping the gap between research and clinical adoption.

Mark D Gustavson1, David L Rimm2, Marisa Dolled-Filhart3.   

Abstract

The use of tissue microarrays (TMAs) in the preclinical and translational research settings has become ubiquitous as they allow for high-throughput in situ biomarker analysis of hundreds of patient samples, with time and cost efficiency. Coupled with advanced imaging and image-analysis technologies that allow for objective and standardized biomarker expression assessment, TMAs have become critical tools for the development and validation of clinically meaningful biomarker diagnostic assays. However, their diagnostic use in the clinical laboratory setting is limited due to the need for conventional whole-section tissue assessment used for routine diagnostic purposes. In this article, after reviewing TMA basics and their translational and clinical research applications, we will focus on the use of TMAs for robust assay development and quality control in the clinical laboratory setting, as well as provide insights into how TMAs may serve well in the clinical setting as assay performance and quantification controls.

Entities:  

Keywords:  assay development; biomarker; clinical application; diagnostic testing; digital pathology; quality control; tissue microarray

Year:  2013        PMID: 29758838     DOI: 10.2217/pme.13.42

Source DB:  PubMed          Journal:  Per Med        ISSN: 1741-0541            Impact factor:   2.512


  5 in total

1.  Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry.

Authors:  Daniel E Carvajal-Hausdorf; Jonathan Patsenker; Kelly P Stanton; Franz Villarroel-Espindola; Amanda Esch; Ruth R Montgomery; Amanda Psyrri; Konstantine T Kalogeras; Vassiliki Kotoula; George Foutzilas; Kurt A Schalper; Yuval Kluger; David L Rimm
Journal:  Clin Cancer Res       Date:  2019-02-22       Impact factor: 12.531

Review 2.  Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic.

Authors:  Daniel E Carvajal-Hausdorf; Kurt A Schalper; Veronique M Neumeister; David L Rimm
Journal:  Lab Invest       Date:  2014-12-15       Impact factor: 5.662

3.  Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms.

Authors:  Amy R Peck; Melanie A Girondo; Chengbao Liu; Albert J Kovatich; Jeffrey A Hooke; Craig D Shriver; Hai Hu; Edith P Mitchell; Boris Freydin; Terry Hyslop; Inna Chervoneva; Hallgeir Rui
Journal:  Mod Pathol       Date:  2016-06-17       Impact factor: 7.842

4.  The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation.

Authors:  Guray Akturk; Michael Angelo; Elizabeth L Engle; Sacha Gnjatic; Shirley Greenbaum; Noah F Greenwald; Cyrus V Hedvat; Travis J Hollmann; Jonathan Juco; Edwin R Parra; Marlon C Rebelatto; David L Rimm; Jaime Rodriguez-Canales; Kurt A Schalper; Edward C Stack; Janis M Taube; Cláudia S Ferreira; Konstanty Korski; Ana Lako; Scott J Rodig; Emanuel Schenck; Keith E Steele; Michael J Surace; Michael T Tetzlaff; Katharina von Loga; Ignacio I Wistuba; Carlo B Bifulco
Journal:  J Immunother Cancer       Date:  2020-05       Impact factor: 13.751

5.  Antibody validation for protein expression on tissue slides: a protocol for immunohistochemistry.

Authors:  Tyler MacNeil; Ioannis A Vathiotis; Sandra Martinez-Morilla; Vesal Yaghoobi; Jon Zugazagoitia; Yuting Liu; David L Rimm
Journal:  Biotechniques       Date:  2020-08-27       Impact factor: 1.993

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.